Novo Nordisk’s NDA filing for CagriSema positions the first fixed-dose amylin–GLP-1 combination as a potential ...

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024. Novartis ...

Roche’s executives at JP Morgan 2025 spoke candidly about the company’s need to be more deliberate in its approach on how ...

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

In today’s Pharmaceutical Executive Daily, President Trump announces nine additional participants in the TrumpRx program, ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...

Lilly’s return to the JP Morgan Healthcare Conference comes as the company seeks to shift the narrative from last year’s ...

The FDA has approved Novo Nordisk’s Wegovy pill to reduce excess body weight, support weight management, and maintain weight ...

Sanofi has announced that Paul Hudson, CEO, will be in attendance at the 44 th annual JP Morgan Healthcare Conference in San ...

Harbour BioMed announced it has entered a multi-year, global strategic collaboration and license agreement with Bristol Myers ...

In today’s Pharmaceutical Executive Daily, the FDA approves Novo Nordisk’s oral Wegovy for chronic weight management, clears ...

On the policy front, the U.S. Senate passed the Biosecure Act, legislation designed to limit federal reliance on certain ...